Vai al contenuto principale
xMedica

NCT06628908ClinicalTrials.gov

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Fase 31100 partecipanti ricercati76 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 7 days after the recorded start)First posted 2024-10-08; recorded start 2024-10-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 92 other studies in this databaseCounted from the lead sponsor named in the record (Vertex Pharmaceuticals Incorporated)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 76 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,100 participants (target), run at 76 sites.

How this score is built
  • Enrolment30/40

    1,100 participants (target)

  • Site count22/25

    76 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 32 months

  • Sponsor scale7/10

    Vertex Pharmaceuticals Incorporated has led 90 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Patologie

  • Diabetic Peripheral Neuropathic Pain

Idoneità

Idoneità
SessoTutti
Età18 Years80 Years
Volontari saniNo

Idoneità come riportata nel registro

Key Inclusion Criteria: * Body weight greater than or equal to (≥) 45 kilogram (kg) * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN * Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period Key Exclusion Criteria: * More than 3 missing daily NPRS scores during the 7-day Baseline Period * Any sensory abnormality (excluding DPN) as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento1100 partecipanti ricercati

Sponsor e collaboratori

  • Vertex Pharmaceuticals Incorporated Sponsor

Bracci e interventi

  • Suzetrigine (SUZ)EXPERIMENTAL

    Participants will be randomized to receive SUZ.

  • PregabalinACTIVE_COMPARATOR

    Participants will be randomized to receive Pregabalin.

  • PlaceboPLACEBO_COMPARATOR

    Participants will be randomized to receive placebo matched to SUZ and Pregabalin.

Interventi

  • Farmaco Placebo (matched to Pregabalin)

    Placebo matched to Pregabalin for oral administration.

  • Farmaco Placebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • Farmaco Pregabalin

    Capsules for oral administration.

  • Farmaco Suzetrigine

    Tablets for oral administration.

Esiti misurati

  1. Esito primario

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo

    Orizzonte temporale From Baseline up to Week 12

  2. Esito secondario

    Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF 36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (pooled with data from Study VX24-548-111)

    Orizzonte temporale From Baseline up to Week 12

  3. Esito secondario

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12 Compared to Pregabalin

    Orizzonte temporale From Baseline up to Week 12

Date

Date
Data di inizio1 ottobre 2024 (effettiva)
Conclusione primaria31 maggio 2027 (stimata)
Conclusione31 maggio 2027 (stimata)
Prima pubblicazione8 ottobre 2024 (effettiva)
Ultimo aggiornamento15 giugno 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltagiugno 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

59 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Albany Medical CollegeAlbanyNew YorkCompletato
Velocity Clinical Research - AlbuquerqueAlbuquerqueNew MexicoIn reclutamento
Synexus Clinical Research- AndersonAndersonSouth CarolinaCompletato
Pinnacle Research Group, LLCAnnistonAlabamaIn reclutamento
Velocity Clinical Research - Baton RougeBaton RougeLouisianaIn reclutamento
Velocity Clinical Research - ClevelandBeachwoodOhioIn reclutamento
Northwest Clinical Research Center (NWCRC)BellevueWashingtonIn reclutamento
Synexus Clinical Research - BirminghamBirminghamAlabamaCompletato
Mass General Brigham - Brigham and Women's Hospital - Main CampusBostonMassachusettsIn reclutamento
Swift Clinical OpCo, IncBrooklynNew YorkIn reclutamento
Clinical Trials of South Carolina - Berkeley - CharlestonCharlestonSouth CarolinaIn reclutamento
M3 Wake Research - CharlestonCharlestonSouth CarolinaIn reclutamento
Feinberg School of Medicine - AnesthesiologyChicagoIllinoisIn reclutamento
Synexus Clinical Research - CincinnatiCincinnatiOhioCompletato
Tandem Clinical Research- CovingtonCovingtonLouisianaIn reclutamento
Synexus Clinical Research - Dallas (DFW) (DRS)DallasTexasCompletato
Zenos Clinical ResearchDallasTexasIn reclutamento
AMR Daphne, ALDaphneAlabamaCompletato
META Medical Research InstituteDaytonOhioIn reclutamento
Accel Research - DelandDeLandFloridaIn reclutamento
Accel Research - DecaturDecaturGeorgiaIn reclutamento
AMR-MiamiDoralFloridaIn reclutamento
Velocity Clinical Research - ProvidenceEast GreenwichRhode IslandIn reclutamento
Velocity Clinical Research - SyracuseEast SyracuseNew YorkIn reclutamento
Velocity Clinical Research - DenverEnglewoodColoradoIn reclutamento
Synexus Clinical Research - EvansvilleEvansvilleIndianaCompletato
Healthcare Research Network - Flossmoor ILFlossmoorIllinoisIn reclutamento
AMR Fort Myers (The Clinical Study Center)Fort MyersFloridaIn reclutamento
Neuro-Pain Medical CenterFresnoCaliforniaIn reclutamento
Velocity Clinical Research - Grants PassGrants PassOregonCompletato
Velocity Clinical Research - Hallandale BeachHallandaleFloridaIn reclutamento
Healthcare Research Network - Hazelwood MOHazelwoodMissouriIn reclutamento
CNS Healthcare - JacksonvilleJacksonvilleFloridaIn reclutamento
AMR Kansas CityKansas CityMissouriIn reclutamento
Accel Research - St. Petersburg-LargoLargoFloridaIn reclutamento
Synexus Clinical Research - Las VegasLas VegasNevadaCompletato
AMR LexingtonLexingtonKentuckyIn reclutamento
Long Beach Research InstituteLong BeachCaliforniaIn reclutamento
Angel City Research, IncLos AngelesCaliforniaIn reclutamento
Accel Research - MaitlandMaitlandFloridaCompletato
HRI - Hassman Research InstituteMarltonNew JerseyCompletato
Velocity Clinical Research - MedfordMedfordOregonIn reclutamento
Suburban Research Associates - MediaMediaPennsylvaniaIn reclutamento
Velocity Clinical Research - BoiseMeridianIdahoIn reclutamento
Suncoast Research Associates - MiamiMiamiFloridaIn reclutamento
3Sync Research - Miami LakesMiami LakesFloridaIn reclutamento
West Clinical ResearchMorehead CityNorth CarolinaIn reclutamento
AMR Nashville, TNNashvilleTennesseeCompletato
Suncoast Clinical Research - New Port RicheyNew Port RicheyFloridaIn reclutamento
Columbia Presbyterian - The Neurological Institute of New YorkNew YorkNew YorkIn reclutamento

Nella scheda del registro sono indicati altri 26 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.

Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.